NOTICE OF THE 2023 ANNUAL GENERAL MEETING
KAINOS GROUP PLC
(INCORPORATED IN ENGLAND AND WALES UNDER COMPANY NUMBER 9579188)

Notice of the 2023 Annual General Meeting of Kainos Group plc, to be held at Kainos House, 4-6 Upper Crescent, Belfast, BT7 1NT on Thursday 21 September 2023 at 10:30 a.m., is set out in this document.

Whether or not you propose to attend the meeting, please complete and submit a proxy appointment in accordance with the notes to this Notice of Annual General Meeting. To be valid, the proxy appointment must be received no later than 10:30 a.m. on Tuesday 19 September 2023.

Appointment of a proxy will not prevent shareholders from attending and voting in person at the 2023 Annual General Meeting should they wish to do so.

A proxy may be appointed and votes cast electronically via www.signalshares.com or through the CREST electronic proxy appointment service (details of which are set out in notes 3 and 4 in the notes to this Notice of Annual General Meeting).

The Board considers the proposed resolutions as set out in this Notice of Annual General Meeting are likely to promote the success of the Company and are in the best interests of the Company and its shareholders as a whole. The Directors unanimously recommend that shareholders vote in favour of the resolutions as they intend to do in respect of their own beneficial holdings (save in respect of matters in which they are themselves interested) which amount in aggregate to 18,909,582 shares representing approximately 15% of the existing issued ordinary share capital of the Company as of 25 July 2023.

If you require assistance, please contact Link Group, whose contact details are set out in this document.

This document is important and requires your immediate attention
If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, you should seek your own personal financial advice immediately from your stockbroker, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000 if you are resident in the United Kingdom or, if you are not, from another appropriately authorised independent financial adviser.

If you have sold or transferred all of your shares, please pass this document and any other documents that accompany it as soon as possible to the purchaser or transferee or to the person who arranged the sale or transfer so that they can pass these documents to the person who now holds the shares. If you have sold or otherwise transferred only part of your holding, you should retain this document and its enclosures.
NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the eighth Annual General Meeting of Kainos Group plc (the Company) will be held at Kainos House, 4-6 Upper Crescent, Belfast, on Thursday 21 September 2023 at 10:30 a.m. for the following purposes:

**Ordinary Resolutions**
To consider and, if thought fit, pass the following resolutions as Ordinary Resolutions:

1. To receive the Company’s audited accounts and financial statements and the auditor’s and Directors’ reports on the accounts and financial statements for the year ended 31 March 2023.

2. To approve the Directors’ Remuneration Report (excluding the Directors’ Remuneration Policy) for the year ended 31 March 2023.

3. To declare a final dividend of 16.1 pence per ordinary share in respect of the year ended 31 March 2023.

4. To re-elect Mr Richard McCann as a Director of the Company.

5. To re-elect Mr Andy Malpass as a Director of the Company.

6. To re-elect Mr Tom Burnet as a Director of the Company.

7. To re-elect Mrs Katie Davis as a Director of the Company.

8. To re-elect Mrs Rosaleen Blair as a Director of the Company.

9. To re-appoint KPMG as the Company’s auditor.

10. To authorise the Audit Committee to agree the remuneration of the auditor of the Company.

11. To authorise the Directors generally and unconditionally, pursuant to section 551 of the Companies Act 2006 (the Act), to exercise all powers of the Company to allot shares in the Company and/or to grant rights to subscribe for, or to convert any security into shares in the Company:

   (a) up to a maximum aggregate nominal amount of £207,985.32 (such amount to be reduced by the nominal amount of any equity securities (within the meaning of section 560 of the Act) allotted under paragraph (b) below; and

   (b) comprising equity securities (within the meaning of section 560 of the Act) in connection with a rights issue (as referred to in the Financial Conduct Authority’s listing rules) or pursuant to any arrangements made for the placing or underwriting or other allocation of any shares or other securities included in, but not taken up under, such rights issue up to a maximum aggregate nominal amount of £415,970.64 (such amount to be reduced by any shares allotted or rights granted under sub-paragraph (a) above), provided that these authorities replace any existing authorities vested in the Directors on the date of this Notice of Annual General Meeting to allot shares and/or grant rights that remain unexercised at the commencement of the 2023 Annual General Meeting and unless renewed or revoked, shall expire on the earlier of the conclusion of the next Annual General Meeting of the Company and the close of business on 30 September 2024 but so as to enable the Company before such date to make offers or agreements which would or might require shares to be allotted and/or rights to be granted after such expiry and the Directors may allot shares and/or grant rights in pursuance of such offer or agreement as if the authorities conferred under this resolution had not expired.

**Special Resolutions**
To consider, and if thought fit, pass the following resolutions as Special Resolutions:

12. Subject to the passing of resolution 11 above, to empower the Directors in accordance with sections 570 to 573 of the Act, until the earlier of the conclusion of the next Annual General Meeting of the Company and the close of business on 30 September 2024, to make allotments of equity securities (as construed in accordance with section 560 of the Act) for cash under the authorities conferred by resolution 11 above or by way of sale of treasury shares, as if section 561 of the Act did not apply to any such allotment (or sale), such powers being limited to the allotment of equity securities on sale of treasury shares:

   (a) in connection with an issue or offer by way of rights in favour of holders of equity securities and of any other person in proportion (as nearly as may be practicable) to their respective holdings or in accordance with the rights attaching thereto (but with such exclusions or other arrangements as the Directors may deem necessary or expedient to deal with fractional entitlements, the use of more than one currency for the making of payments in respect of such offer, record dates or other legal or practical problems in or under the laws of, or any requirements of any recognised regulatory body or stock exchange in, any territory or as regards shares held by an approved depositary or in issue in uncertificated form or otherwise however); and
(a) above up to a maximum aggregate nominal amount of £31,197.80,

save that the Company may, before expiry of those powers, make an offer or agreement which would, or might, require equity securities to be allotted after such expiry and the Directors may allot equity securities (and sell treasury shares) pursuant to any such offer or agreement as if the powers had not expired.

13. Subject to the passing of resolution 11, and in addition to the powers contained in resolution 12, to empower the Directors, until the earlier of the conclusion of the next Annual General Meeting of the Company and the close of business on 30 September 2024, to make allotment of equity securities (as construed in accordance with section 560 of the Act) for cash pursuant to the authorities that were conferred on the Directors by resolution 11 above or by way of sale of treasury shares as if section 561 of the Act did not apply to any such allotment or sale, such powers being limited to the allotment of equity securities or the sale of treasury shares:

(a) up to a maximum aggregate nominal amount of £31,197.80; and

(b) used only for the purposes of financing (or re-financing, if such re-financing occurs within six months after the date of the original transaction) a transaction which the Directors determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this Notice of Annual General Meeting,

save that the Company may, before expiry of those powers, make an offer or agreement which would, or might, require equity securities to be allotted (and treasury shares to be sold) after such expiry and the Directors may allot equity securities (and sell treasury shares) pursuant to any such offer or agreement as if such powers had not expired.

14. That the Company is generally and unconditionally authorised for the purposes of section 701 of the Act to make market purchases (as defined in section 693 of the Act) of its ordinary shares upon such terms and in such manner as the Directors of the Company shall determine provided that:

(a) the maximum number of ordinary shares hereby authorised to be purchased is 12,479,119;

(b) the minimum price (exclusive of expenses) which may be paid for such a share is its nominal value;

(c) the maximum price (exclusive of expenses) which may be paid for such a share shall be the higher of:

(i) 5% above the average of the middle market quotation of an ordinary share of the Company taken from the London Stock Exchange Daily Official List for the five business days immediately preceding the date on which the purchase is made; and/or

(ii) the price of the last independent trade and the highest current independent trade on the trading venues where the purchase is carried out and the highest current independent bid on the trading venues where the purchase is carried out;

(d) the authority hereby conferred shall (unless previously renewed or revoked) expire on the earlier of the conclusion of the Company’s next Annual General Meeting and the close of business on 30 September 2024;

(e) the Company may make a contract or contracts to purchase ordinary shares under the authority hereby conferred prior to the expiry of such authority which will or may be executed wholly or partly after the expiry of such authority and may make a purchase of ordinary shares in pursuance of any such contract or contracts as if the authority conferred had not expired.

15. That any general meeting of the Company, other than an Annual General Meeting, may be called by not less than 14 clear days’ notice.

Registered office: Kainos Group plc
2nd Floor
21 Farringdon Road
London EC1M 3HA

By order of the Board: Gráinne Burns
Company Secretary
10 August 2023
NOTES

1. A member who is entitled to vote at the meeting is entitled to appoint one or more proxies to exercise all or any of such member’s rights to vote on behalf of the member at the Annual General Meeting. Members may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. Members may not appoint more than one proxy to exercise rights attached to any one share. A proxy need not be a member of the Company.

2. The right of a member of the Company to vote at the meeting will be determined by reference to the register of members. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001 and the Company’s Articles of Association, the time by which a person must be entered on the register of members in order to have the right to vote at the Annual General Meeting is by the close of business on Tuesday 19 September 2023 (or, if the meeting is adjourned, at the close of business on the date two working days before the time fixed for the adjourned meeting). Changes to entries on the register of members after the relevant time will be disregarded in determining the rights of any person to attend or vote at the meeting.

3. A member may appoint a proxy online by following the instructions for the electronic appointment of a proxy at www.signalshares.com. You will need your Investor Code which is set out on your share certificate which is available from the Registrar. To be a valid proxy appointment, the member’s electronic message confirming the details of the appointment completed in accordance with those instructions must be transmitted to be received by 10:30 a.m. on Tuesday 19 September 2023. Members who hold their shares in uncertificated form may use the CREST electronic proxy appointment service to appoint a proxy electronically, as explained below. If you require assistance, please contact Link Group whose contact details are set out at Note 7 below.

4. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so by using the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed one or more voting service providers, should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf. In order for a proxy appointment or a proxy instruction made using the CREST electronic proxy appointment service to be valid, the appropriate CREST message (CREST proxy appointment instruction) must be properly authenticated in accordance with the specifications of CREST’s operator, Euroclear UK & International Limited (Euroclear), and must contain all the relevant information required by the CREST Manual. To be valid, the message (regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy) must be transmitted so as to be received by Link Group (ID RA10), as the Company’s “issuer’s agent”, by 10:30 a.m. on Tuesday 19 September 2023. After this time, any change of instruction to a proxy appointed through the CREST system should be communicated to the appointee through other means. The time of the message’s receipt will be taken to be when (as determined by the timestamp applied by the CREST Applications Host) the issuer’s agent is first able to retrieve it by enquiry through the CREST system in the prescribed manner. Euroclear does not make available special procedures in the CREST system for transmitting any particular message. Normal system timings and limitations apply in relation to the input of CREST proxy appointment instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or a CREST sponsored member or has appointed any voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s) such action as is necessary to ensure that a message is transmitted by means of the CREST system by any particular time. CREST members and, where applicable, their CREST sponsors or voting service providers should take into account the provisions of the CREST Manual concerning timings as well as its section on “Practical limitations of the system”. In certain circumstances the Company may, in accordance with the Uncertificated Securities Regulations 2001 or the CREST Manual, treat a CREST proxy appointment instruction as invalid.

5. If you are an institutional investor you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 10:30 a.m. on 19 September 2023 in order to be considered valid or, if the meeting is adjourned, by the time which is 48 hours before the time of the adjourned meeting. Before you can appoint a proxy via this process you will need to have agreed to Proxymity’s associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy. An electronic proxy appointment via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your proxy vote.

6. Appointing a proxy will not prevent a member from attending and voting in person at the meeting should he so wish. Unless otherwise indicated on the Form of Proxy, CREST, Proxymity or any other electronic voting instruction, the proxy will vote as they think fit or, at their discretion, withhold from voting.

7. Hard copy forms for the appointment of a proxy can be obtained by contacting the Company’s Registrar, Link Group on 0371 664 0300 or, from overseas, on +44 (0) 371 664 0300. Within the United Kingdom, calls are charged at standard geographic rate and will vary by provider. Calls from outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 a.m. to 5:30 p.m., Monday to Friday, excluding public holidays in England and Wales. To be valid, a proxy appointment form must be completed in accordance with the instructions that accompany it and then delivered (together with any power of attorney or other authority under which it is signed, or a certified copy of such item) so as to be received by 10:30 a.m. on Tuesday 19 September 2023, to:
UK based members:
FREEPOST SAS, Link Group, 10th Floor, Central Square,
29 Wellington Street, Leeds, LS1 4DL.

Non-UK based members:
Link Group, Central Square, 29 Wellington Street, Leeds,
United Kingdom LS1 4DL.

8. Any person to whom this notice is sent who is currently
nominated by a member of the Company to enjoy
information rights under section 146 of the Act
(nominated person) may have a right under an agreement
between him and that member to be appointed, or to have
someone else appointed, as a proxy for the meeting. If a
nominated person has no such right or does not wish to
exercise it, he may have a right under such an agreement
to give instructions to the member concerned as to the
exercise of voting rights. The statement in note 1 above of
the rights of a member in relation to the appointment of
proxies does not apply to a nominated person. Such rights
can only be exercised by the member concerned.

9. A member wishing to attend and vote at the meeting in
person should arrive prior to the time fixed for its
commencement. A member that is a corporation can only
attend and vote at the meeting in person through one or
more representatives appointed in accordance with
section 323 of the Act. Any such representative should
bring to the meeting written evidence of his appointment,
such as a certified copy of a board resolution of, or a letter
from, the corporation concerned confirming the
appointment. Any member wishing to vote at the meeting
without attending in person or (in the case of a
corporation) through its duly appointed representative
must appoint a proxy to do so.

10. As of 25 July 2023 (the latest practicable date prior to
the printing of this document) (i) the Company’s issued
share capital consisted of 124,791,193 ordinary shares of
0.5 pence each, carrying one vote each, and (ii) the total
voting rights in the Company were 124,791,193.

11. Voting on all resolutions at the 2023 Annual General
Meeting will be by way of a poll rather than on a show of
hands. Poll voting is in line with practice increasingly
adopted by UK public companies and provides a more
accurate reflection of the views of members by ensuring
that every vote is recognised, including the votes of those
members who are unable to attend but who have
appointed a proxy for the meeting. On a poll each
member has one vote for every share held.

12. Each member attending the meeting has the right to ask
questions relating to the business being dealt with at the
meeting which, in accordance with section 319A of the Act
and subject to some exceptions, the Company must cause
to be answered. Information relating to the meeting which
the Company is required by the Act to publish on a
website in advance of the meeting may be viewed at
www.kainos.com. A member may not use any electronic
address provided by the Company in this document or in
any proxy appointment form or on any website for
communicating with the Company for any purpose in
relation to the meeting other than as expressly stated in it.

13. It is possible that, pursuant to members’ requests made in
accordance with section 527 of the Act, the Company will
be required to publish on a website a statement in
accordance with section 528 of the Act setting out any
matter that the members concerned propose to raise at
the meeting relating to the audit of the Company’s latest
audited accounts. The Company cannot require the
members concerned to pay its expenses in complying with
those sections. The Company must forward any such
statement to its auditor by the time it makes the
statement available on the website. The business which
may be dealt with at the meeting includes any statement
that the Company has been required to publish on its
website.

14. Under section 338 of the Companies Act, members
meeting the threshold requirements set out in that section
have the right to require the Company to give notice of a
resolution which may properly be moved at the AGM. Any
such request, which must comply with s.338(4) of the
Companies Act, must be received by the Company no
later than six weeks before the date fixed for the AGM.

15. Under section 338A of the Companies Act, members
meeting the threshold requirements set out in that section
have the right to require the Company to include a matter
(other than a proposed resolution) in the business to be
dealt with at the AGM. Any such request, which must
comply with s.338A(3) of the Companies Act, must be
received by the Company no later than six weeks before
the date fixed for the AGM.
APPENDIX 1

Explanatory notes to the business of the Annual General Meeting

Resolution 1 – Receipt of the audited accounts and reports

The Companies Act 2006 (the Act) requires the directors of a public company to lay before the company in general meeting copies of the directors’ report, the independent auditor’s report and the audited financial statements of the company in respect of each financial year. The Company proposes, as an ordinary resolution, a resolution to receive its audited accounts and reports for the financial year ended 31 March 2023 (the 2023 Annual Report).

Resolution 2 – Approval of the Directors’ Remuneration Report

In accordance with the Act, shareholders are invited to approve the Directors’ Remuneration Report for the financial year ended 31 March 2023. The Directors’ Remuneration Report is set out in the 2023 Annual Report on pages 76 to 94. The vote on this resolution is advisory only and the Directors’ entitlement to remuneration is not conditional on its being passed. For the purposes of this resolution, the Directors’ Remuneration Report does not include the Directors’ Remuneration Policy (which is set out on pages 78 to 85 of the 2023 Annual Report).

Resolution 3 – Declaration of a final dividend

The Directors are recommending payment of a final dividend for the financial year ended 31 March 2023 of 16.1 pence per ordinary share. If approved by ordinary resolution of the shareholders, the dividend will be payable on 20 October 2023 to shareholders on the register of members as at the close of business on 29 September 2023.

Resolutions 4-8 – Election and re-election of Directors

Resolutions 4 to 8 relate to the retirement and subsequent re-election of the Company’s Directors. Under Article 95 of the Company’s Articles of Association, one-third of the Directors shall retire at the Annual General Meeting held in the third calendar year following the year in which they were elected or last re-elected but, unless otherwise agreed, shall be eligible for re-election. Notwithstanding the requirements prescribed by the Company’s Articles of Association, the Board has agreed that in accordance with the UK Corporate Governance Code (the Code), the entire Board will offer themselves for re-election at the 2023 Annual General Meeting and separate resolutions will be proposed for each.

Following completion of the Company’s annual board evaluation exercise, it is the view of the Board that the Executive and Non-Executive Directors offering themselves for re-election continue to perform effectively, make a positive contribution and demonstrate commitment to their roles and that it is appropriate for them to continue to serve as Directors of the Company. The Board accordingly supports the re-election of those Directors. Taking into account the independence criteria set out in the Code, the Board considers Tom Burnet, Andy Malpass, Katie Davis and Rosaleen Blair to be independent in character and judgement. Further information relating to the experience, skills and background of each of the Directors standing for election or re-election is set out in Appendix 2.

As announced on 2 May 2023, the Board will be appointing James Kidd as a Director with effect from 1 October 2023 under the power in the Articles for the Board to appoint directors. James Kidd will stand for election in 2024.

As announced on 19 June 2023, Brendan Mooney will complete his term as CEO at the conclusion of this year’s AGM and will not be standing for re-election.

Following the AGM the Board will be appointing Russell Sloan as a Director and CEO with effect from 21 September 2023 under the power in the Articles for the Board to appoint directors. Russell Sloan will stand for election in 2024.

Copies of the contracts of service between the Directors and the Company are available for inspection at the registered office of the Company during usual business hours on each business day.

Resolutions 9 and 10 – Re-appointment and remuneration of the auditor

The Company is required to appoint or re-appoint an auditor at each Annual General Meeting at which its audited accounts and reports are presented to shareholders. The Audit Committee has recommended to the Board, and resolution 9 therefore proposes, the re-appointment of KPMG as auditor (to hold office until the next such meeting). The Audit Committee has confirmed to the Board that its recommendation is free from third party influence, and that no restrictive contractual provisions have been imposed on the Company limiting the choice of auditor. Resolution 10 authorises the Audit Committee to determine KPMG’s remuneration.

Resolution 11 – Authority to allot shares

The Directors currently have a general authority to allot new shares in the Company and to grant rights to subscribe for, or convert any securities into, shares. This authority is, however, due to expire at the 2023 Annual General Meeting and the Board would like to renew it to provide the Directors with flexibility to allot new shares and grant rights up until the Company’s next Annual General Meeting within the limits prescribed by the Investment Association.

The Investment Association’s guidelines on directors’ allotment authority state that the Association’s members will regard as routine any proposal at a general meeting to seek a general authority to allot an amount up to two-thirds of the existing share capital, provided that any amount in excess of one-third of the existing share capital is applied to fully pre-emptive rights issues only.

Accordingly, if passed, this resolution will authorise the Directors to allot (or grant rights over) new shares in the Company (i) in connection with a rights issue in favour of ordinary shareholders up to an aggregate nominal amount of £415,970.64 (representing approximately 66% of the Company’s issued ordinary share capital as of 25 July 2023 (being the latest practicable date prior to publication of this document)) (such amount being reduced by any shares allotted or rights granted under sub-paragraph (a) of the
resolution), and (ii) in other situations up to an aggregate nominal amount of £207,985.32 (representing approximately 33% of the Company’s issued ordinary share capital as of 25 July 2023 (being the latest practicable date prior to publication of this document)) (such amount being reduced by the amount of any shares allotted or rights granted under sub-paragraph (b) of the resolution in excess of 33% of the Company’s issued ordinary share capital).

In each case, the authority lasts until the close of business on 30 September 2024 or, if earlier, until the end of the next Annual General Meeting. These authorities succeed those granted in 2022.

The Directors have no current intention to exercise these authorities; however, it is considered prudent to maintain the flexibility that these authorities provide (especially in case appropriate opportunities arise). If they do exercise these authorities, the Directors intend to follow best practice regarding their use, as recommended by the Investment Association.

As of 25 July 2023, the Company did not hold any treasury shares.

**Resolutions 12 and 13 – Disapplication of pre-emption rights**

Resolutions 12 and 13 are special resolutions which, if passed, will disapply statutory pre-emption rights and enable the Directors to allot shares in the Company, or to sell any shares out of treasury, for cash, without first offering those shares to existing shareholders in proportion to their existing shareholdings.

The proposed resolutions essentially replicate the powers which were granted at last year’s Annual General Meeting (and which will expire at the 2023 Annual General Meeting). Such powers reflect the Statement of Principles published by the Pre-Emption Group in March 2015, which provide that a company may seek power to allot on a non-pre-emptive basis for cash shares in any one year representing: (i) no more than 5% of the company’s issued ordinary share capital in any one year; and (ii) no more than an additional 5% of the company’s issued ordinary share capital provided that such additional power is only used in connection with an acquisition or specified capital investment. In line with best practice the Company has structured its pre-emption disapplication request as two separate resolutions.

If resolution 12 is passed, it will permit the Directors to allot ordinary shares on a non-pre-emptive basis and for cash both in connection with a rights issue or similar pre-emptive issue and, otherwise than in connection with any such issue, up to a maximum aggregate nominal amount of £31,197.80. This amount represents not more than 5% of the Company’s issued ordinary share capital (excluding treasury shares) as of 25 July 2023 (being the latest practicable date prior to publication of this document). This resolution will permit the Directors to allot any such shares for cash in any circumstances (whether or not in connection with an acquisition or specified capital investment).

If resolution 13 is passed, it will allow the Directors an additional power to allot ordinary shares on a non-pre-emptive basis and for cash up to a further maximum aggregate nominal amount of £31,197.80. This amount represents not more than 5% of the Company’s issued ordinary share capital (excluding treasury shares) as of 25 July 2023 (being the latest practicable date prior to publication of this document). The Directors shall use any power conferred by resolution 13 only in connection with an acquisition or specified capital investment (of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this Notice) which is announced contemporaneously with the issue, or which has taken place in the preceding six-month period and is disclosed in the announcement at the time.

The Pre-Emption Group published a revised statement of principles for the disapplication of pre-emption rights in November 2022. The Board have decided that they do not wish to increase the disapplication threshold at the current time, but will continue to monitor market practice. Therefore, resolutions 12 and 13 seek authority from shareholders under the previous Statement of Principles for the disapplication of pre-emption rights published in 2015.

The Board confirms its intention to continue to follow the provisions of the 2015 Statement of Principles regarding cumulative usage of authorities within a rolling three-year period. Those Principles provide that a company should not issue shares for cash (other than to satisfy share scheme requirements) representing more than 7.5% of the company’s issued share capital in any rolling three-year period, other than to existing shareholders, without prior consultation with shareholders. This limit excludes any ordinary shares issued pursuant to a general disapplication of pre-emption rights in connection with an acquisition or specified capital investment.

**Resolution 14 – Purchase of own shares**

This special resolution, if passed, will authorise the Company to make market purchases of its own ordinary shares up until the conclusion of the Company’s next Annual General Meeting or, if earlier, the close of business on 30 September 2024, subject to specific conditions relating to price and volume. The maximum number of ordinary shares which may be purchased under this authority is 12,479,119, representing approximately 10% of the Company’s issued ordinary share capital as of 25 July 2023 (being the latest date prior to publication of this document).

The Company’s exercise of this authority is subject to the upper and lower limits on the price payable set out in the resolution.

The Directors have no present intention of exercising this authority but wish to have the flexibility to do so in the future. Shares would only be purchased if the Directors believed that to do so would result in an improvement in earnings per share and would be in the best interests of shareholders generally. Any purchases would be made through the London Stock Exchange and purchased shares would be cancelled (in which case the number of shares in issue would thereby be reduced) or, alternatively, held in treasury, depending on which course of action is considered by the Directors to be in the best interests of the shareholders at that time.
As of 25 July 2023, the total number of options to subscribe for ordinary shares amounted to 2,221,385, which represents 1.78% of the Company's issued ordinary share capital at that date. The Company does not hold any treasury shares. If the authority being sought by resolution 18 were to be fully exercised, these options would represent 1.98% of the Company's issued ordinary share capital (excluding treasury shares) at that date.

Resolution 15 – Notice of general meetings
This is a special resolution to allow the Company to call general meetings (other than Annual General Meetings) on not less than 14 clear days’ notice.

APPENDIX 1 CONTINUED

APPENDIX 2

Directors’ biographical details
Richard McCann (aged 58)
Chief Financial Officer (CFO)/Chief Operating Officer (COO)
Richard is a Fellow of the Institute of Chartered Accountants in Ireland and trained with Coopers & Lybrand, before moving into industry with Galen Holdings plc. Richard joined Galen as financial controller of a start-up subsidiary in the US and subsequently became Senior Vice President in charge of Corporate Finance, with responsibility for the organisation’s acquisitions and investor relations. He was Managing Director of two subsidiaries in the Almac Group, including a US subsidiary that provides software development services for pharmaceutical companies. Richard joined Kainos in 2011 and was appointed to the Board on the Company’s admission to the market on 10 July 2015.

Andy Malpass (aged 61)
Independent Non-Executive Director
Andy graduated with a BA (Hons) in Accounting and Finance from Lancaster University and is a Fellow of the Chartered Institute of Management Accountants. He has over 30 years’ experience in the software industry covering both private and public companies. Most recently, Andy was Group Finance Director of Fidessa Group plc (formerly Royalblue Group plc) which he joined in 1995, and where he has also been Company Secretary. In June 2018, Andy was appointed as a Non-Executive Director and chair of the Audit Committee of accesso Technology Group plc. Andy was appointed to the Board on the Company’s admission to the market on 10 July 2015. He is Chair of the Audit Committee.

Tom Burnet (aged 55)
Independent Non-Executive Director
Tom graduated with an MBA from the University of Edinburgh. In addition to his responsibilities at Kainos, Tom is Non-Executive Chairman of The Baillie Gifford US Growth Trust plc and Non-Executive Chairman at Aker Systems. He is also a Non-Executive Director for the BMO Private Equity Trust. He started his career as an Army Officer serving in the Black Watch (R.H.R.) and is a member of the King’s Bodyguard in Scotland. Tom was appointed Company Chair on 26 September 2019, having joined the Board at the Company’s admission to the market in July 2015. He is Chair of the Nominations Committee and a member of the Remuneration Committee.

The Company currently has the power to call a general meeting (other than an Annual General Meeting) on at least 14 days’ notice to the shareholders and would like to preserve this ability. In order to do so, shareholders must first approve the calling of meetings on at least 14 days’ notice. This resolution seeks such an approval. The approval will be effective until the Company’s next Annual General Meeting. A minimum 14-day notice period would not be used as a matter of routine for such meetings, but only exceptionally where it is merited by the business of the meeting and is considered to be in the interests of shareholders as a whole.

Katie Davis (aged 58)
Independent Non-Executive Director
Katie holds a BS in Electrical Engineering from the University of Illinois at Champaign/Urbana. She is an experienced leader, with a strong track record for delivery in both the public and private sectors. She joined Accenture’s Chicago office in 1987, moving to London in 1988 and becoming a partner in Accenture’s Customer Relationship Management practice in 2000.

In 2005, Katie joined the Cabinet Office, with responsibility for increasing the capacity and capability of UK central government and the wider public sector, to deliver large-scale IT-enabled business change. She subsequently held several senior positions in the Cabinet Office, Home Office, Department of Health and NHS. In 2012, Katie was named one of the 25 most influential women in IT by Computer Weekly.

Katie was appointed to the Board on 28 November 2019. She is Chair of the Remuneration Committee and a member of the Audit Committee and Nominations Committee.

Rosaleen Blair (aged 57)
Independent Non-Executive Director
Rosaleen is the Founder and Chair of Alexander Mann Solutions (AMS), a pioneer in the global workforce solutions industry. She served as CEO of AMS for 25 years, leading the business from a start-up to a global business working in partnership with clients such as Deloitte, HSBC, Novo Nordisk, Rolls-Royce and Santander. AMS has 11,000 employees and operates in 100 countries.

Rosaleen is a serial entrepreneur and adviser to numerous companies. She is also the Chair of Everywoman, an organisation dedicated to the advancement of women in business. Rosaleen is involved in several not-for-profit initiatives, notably serving as Chair of the London Irish Centre and as an Enterprise Fellow of the Prince’s Trust. She is the returning Chair of EY’s World Entrepreneur of the Year Awards in 2022.

Rosaleen is recognised as an industry leader and entrepreneur, winning numerous awards including Veuve Clicquot Businesswoman of the Year (2007) and EY London Entrepreneur of the Year (2006). She was awarded a CBE for services to business and recruitment. Rosaleen was appointed to the Board on 1 January 2021. She is a member of the Nominations Committee, Remuneration Committee and the Audit Committee.